Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM

Kekkaku

Volumn 81, Issue 4, 2006, Pages 329-335

  Kawata, Noriko ^a   Kawahara, Shin ^b   Tada, Atsuhiko ^a   Takigawa, Nagio ^a   Shibayama, Takuo ^a   Soda, Ryo ^a   Takahashi, Kiyoshi ^a  

^a Department of Internal Medicine   (Japan)

^b Kawahara Internal Medicine   (Japan)

Author keywords

Antimycobacterial susceptibility; BrothMIC NTM; Minimum inhibitory concentration (MIC); Nontuberculous mycobacteria

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM KANSASII;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM KANSASII;

EID: 33746562472     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Prince DS, Peterson DD, Steiner RM, et al.: Infection with Mycobacterium avium complex in patients without predisposing conditions. N Eng J Med. 1989; 321: 863-868.
2. Japanese source
3. Reich JM, Johnson RE: Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern: the Lady Windermere Syndrome. Chest. 1992; 101: 1605-1609.
4. Japanese source
5. Heifets L: Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother. 1996; 40: 1759-1767.
6. Wallace RJ, Nash DR, Steele LC, et al.: Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 Broth. J Clin Microbiology. 1986; 24: 976-981.
7. Dautzenberg B, Truffot C, Legris S, et al.: Activity of clarithromycin against Mycobacterium avium complex infection in AIDS patient: a controlled clinical trial. Am Rev Respir Dis. 1991; 144: 564-569.
8. Wallace RJ, Brown BA, Griffith DE, et al.: Clarithromycin regimens for pulmonary Mycobacterium avium complex. Am J Respir Crit Care Med. 1996; 153: 1766-1772.
9. Heifets LB: Clarithromycin against Mycobacterium avium complex infections. Tubercle and Lung Disease. 1996; 77: 19-26.
10. American Thaoracic Society: Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997; 156: S1-S25.
11. Wallace RJ, Brown BA, Griffith DE, et al.: Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med. 1994; 149: 1335-1341.
12. Japanese source
13. Tomioka H, Sato K, Shimizu T, et al.: Anti-mycobacterium tuberculous activities of new fluoloquinolones in combination with other antituberculous drugs. Journal of Infection. 2002; 44: 160-165.
14. Alangaden GJ, Lerner SA: The clinical use of fluoroquinolones for the treatment of mycobacterial disease. Clin Infect Dis. 1997; 25: 1213-1221.
15. Berning SE: The role of fluoroquinolone in tuberculosis today. Drugs. 2001; 61: 9-18.
16. Takayama K, Kilburn JO: Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother. 1989; 33: 1493-1499.
17. Belanger AE, Besra GS, Ford M, et al.: The cmbAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci. 1996; 93: 11919-11924.
18. David HL: Basis for lack of drug susceptibility of atypical mycobacteria. Rev Infect Dis. 1981; 3: 878-884.
19. Rastogi N, Frenhel C, Ryter A, et al.: Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for the exclusion of antimicrobial agents? Antimicrob Agents Chemother. 1981; 20: 666-677.
20. Japanese source